Literature DB >> 21133632

Intravesical bacillus Calmette-Guerin (BCG) instillation for primary and recurring T1G3 bladder cancers.

Takehiko Okamura1, Hidetoshi Akita, Ryosuke Ando, Yasunori Kawai, Keiichi Tozawa, Kenjiro Kohri.   

Abstract

INSTRUCTION: With T1G3 bladder cancer, it remains unresolved whether the best treatment option is bladder preservation or total cystectomy. To assess the feasibility of the first option, we performed a clinical evaluation of the efficacy of intravesical instillation of bacillus Calmette-Guerin (BCG) for prevention of T1G3 bladder cancer recurrence after transurethral resection of bladder tumor (TUR-Bt).
METHODS: A total of 30 patients with T1G3 bladder cancers received 6 to 8 weekly instillations of BCG followed in some cases by further applications at monthly intervals.
RESULTS: Recurrence occurred in 13 cases. There were 6 patients with progression, total cystectomy being performed for 5 of these. Further BCG-including treatments were performed in 7 patients, and all of them were alive at the end of the follow-up period. Finally, bladder preservation proved successful in 24 of 30 cases.
CONCLUSION: Intravesical instillation of BCG in high-risk T1G3 cases, including additional BCG treatment, proved effective and satisfactory in our series. Therefore, this option warrants emphasis with regard to its relative merit compared to total cystectomy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21133632

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  1 in total

1.  Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.

Authors:  Makito Miyake; Kota Iida; Nobutaka Nishimura; Tatsuki Miyamoto; Kiyohide Fujimoto; Ryotaro Tomida; Kazumasa Matsumoto; Kazuyuki Numakura; Junichi Inokuchi; Shuichi Morizane; Takahiro Yoneyama; Yoshiaki Matsumura; Takashige Abe; Masaharu Inoue; Takeshi Yamada; Naoki Terada; Shuya Hirao; Motohide Uemura; Yuto Matsushita; Rikiya Taoka; Takashi Kobayashi; Takahiro Kojima; Yoshiyuki Matsui; Hiroshi Kitamura; Hiroyuki Nishiyama
Journal:  BMC Cancer       Date:  2021-03-11       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.